Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2007-09-18
2007-09-18
Crouch, Deborah (Department: 1632)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S320100, C435S325000
Reexamination Certificate
active
11009357
ABSTRACT:
The present invention relates to methods and compositions for modulating apoptotic pathways. In particular, the present invention relates to methods and compositions for inducing apoptosis in cancer cells. The present invention further relates to methods and compositions for identifying drugs that modulate apoptotic pathways.
REFERENCES:
Mihara et al,(Molecular Cell, 11: 577-590, Mar. 2003.
Marchenko et al, JBC, 276(21): 16202-16212, 2000.
Foster et al., 1999. “Pharmacological rescue of mutant p53 conformation and function,” Science 286:2507-2510.
Bykov et al., 2002. “Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound,” Nat Med 8:282-288.
Moll, 2000. New p53-based strategies for cancer therapy. Eaton Publishing, Natick, MA. 439-455 (BOOK).
Zeimet et al., 2003. “Why did p53 gene therapy fail in ovarian cancer?,” Lancet Oncol. 4:415-422.
Nemunaitis et al., 2000. “Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer,” J Clin. Oncol. 18:609-622.
Kuball et al., 2002 “Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation,” J Clin Oncol. 20:957-965.
Vecil and Lang, 2003.“Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses,” J Neuro. Oncol. 65:237-246.
Herman and Baylin. 2003 “Gene silencing in cancer in association with promoter hypermethylati,”. N Eng. J Med 349:2042-2054.
Concin et al., I. 2004. “Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo,” Cancer Res 64:2449-2460.
Moll et al., 2001 “p53, p63 and p73—solos, alliances and feuds among family members,” Biochim Biophys Acta 1552:47-59.
Schuler and Green. 2001 “Mechanisms of p53-dependent apoptosis,” Biochem Soc Trans 29:684-688.
Moll UM, Slade N. 2004 “p63 and p73: roles in development and tumor formation,” Mol Cancer Res 2: 371-386.
Luo et al., 2001, Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool.
Jacobson et al., “Programmed cell death and Bcl-2 protection in the absence of a nucleus,” Embo J 13:1899-1910 (1994).
Martin et al., 1996 “Phosphatidylserine externalization during CD95-induced apoptosis of cells and cytoplasts requires ICE/CED-3 protease activity.,” J Biol Chem 271 :28753-28756.
Schulze-Osthoff et al., 1994 “Cell nucleus and DNA fragmentation are not required for apoptosis,” J Cell Biol. 127: 15-20.
Marchenko et al., Moll. 2000 “Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling,” J Biol Chem. 275:16202-16212.
Sansome et al., Moll. 2001 “Hypoxia death stimulus induces translocation of p53 protein to mitochondria. Detection by immunofluorescence on whole cells,” FEBS Lett. 488: 110-115.
Mihara et al., Moll. 2003 “p53 has a direct apoptogenic role at the mitochondria,” Molecular Cell, 11: 577-790.
Mihara et al., 2003 “Detection of mitochondrial localization of p53,” Methods Mol Biol 234:203.
Petros et al., 2004. FEBS Letters 28073:1-4.
Schmitt et al., 1999, “INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53.,” Genes Dev 13:2670-2677.
Schmitt et al., 2000 “Genetic analysis of chemoresistance in primary murine lymphomas,” Nat Med 6:1029-1035.
Eischen et al., 2001 “Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.,” Mol Cell Biol 21:7653-7662.
Eischen et al., 2001 “Apoptosis triggered by Myc-induced suppression of Bcl-X (L) or Bcl-2 is bypassed during lymphomagenesis,” Mol Cell Biol 21:5063-5070.
Eischen et al., 1999 “Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis,” Genes Dev 13:2658-2669.
Jacobs et al., 1999 “Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF” Genes Dev. 13:2678-2690.
Lindenboim et al., 2001 “Bcl-x(S) can form homodimers and heterodimers and its apoptotic activity requires localization of Bcl-x(S) to the mitochondria and its BH3 and loop domains,”, Cell Death Differ 8:933-942.
Boise et al., L.H., 1993 “bcl-x, a bcl-2-related gene that functions as a dominant,” Cell 74:597-608.
Moll, et al., 2001, Nuclear and mitochondrial apoptotic pathways of p53, “FEBS Lett”, Mar. 30;493(2-3): 65-9 Review.
Erster, et al. 2004, In vivomitochondrial p53 translocation triggers a rapid first wave of celldeath in repsonse to DNA damage that can precede p53 target gene activation. Mol Cell Biol.Aug. 24 (15): 6728-41.
Erster, et al., 2004, Stress-induced p53 runs a direct mitochondrial death program: its role in physiologic and pathophysiologic stress responses in vivo. “Cell Cycle”, December;3(12):1492-5.
Moll, et al., 2001, Nuclear and mitochondrial apoptotic pathways of p53. FEBS Lett, Mar. 30; 493(2-3): 65-9 Review.
Crouch Deborah
Medlen & Carroll LLP
Sgagias Magdalene
The Research Foundation of State University of New York
LandOfFree
Method for mitochondrial targeting of p53 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for mitochondrial targeting of p53, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for mitochondrial targeting of p53 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3754533